Literature DB >> 15338166

Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis.

Astrid Konrad1, Michael Mähler, Stephan Arni, Beatrice Flogerzi, Sonja Klingelhöfer, Frank Seibold.   

Abstract

BACKGROUND AND AIMS: Anti-TNF-alpha antibodies are very effective in the treatment of acute Crohn's disease, but are limited by the decline of their effectiveness after repeated applications. The stinging nettle leaf extract, IDS 30, is an adjuvant remedy in rheumatic diseases dependent on a cytokine suppressive effect. We investigated the effect of IDS 30 on disease activity of murine colitis in different models.
METHODS: C3H.IL-10-/- and BALB/c mice with colitis induced by dextran sodium sulphate (DSS) were treated with either IDS 30 or water. Mice were monitored for clinical signs of colitis. Inflammation was scored histologically, and faecal IL-1beta and mucosal cytokines were measured by ELISA. Mononuclear cell proliferation of spleen and Peyer's patches were quantified by 3H-thymidine.
RESULTS: Mice with chronic DSS colitis or IL-10-/- mice treated with IDS 30 clinically and histologically revealed significantly (p < 0.05) fewer signs of colitis than untreated animals. Furthermore, faecal IL-1beta and mucosal TNF-alpha concentrations were significantly lower (p < 0.05) in treated mice. Mononuclear cell proliferation after stimulation with lipopolysaccharide was significantly (p < 0.001) reduced in mice treated with IDS 30.
CONCLUSIONS: The long-term use of IDS 30 is effective in the prevention of chronic murine colitis. This effect seems to be due to a decrease in the Th1 response and may be a new therapeutic option for prolonging remission in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338166     DOI: 10.1007/s00384-004-0619-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  34 in total

Review 1.  Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?

Authors:  I D R Arnott; D Watts; S Ghosh
Journal:  Aliment Pharmacol Ther       Date:  2002-05       Impact factor: 8.171

2.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

Review 3.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

4.  Ex-vivo in-vitro inhibition of lipopolysaccharide stimulated tumor necrosis factor-alpha and interleukin-1 beta secretion in human whole blood by extractum urticae dioicae foliorum.

Authors:  B Obertreis; T Ruttkowski; T Teucher; B Behnke; H Schmitz
Journal:  Arzneimittelforschung       Date:  1996-04

5.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.

Authors:  Florian Loher; Kathrin Schmall; Philipp Freytag; Nikola Landauer; Roland Hallwachs; Christian Bauer; Britta Siegmund; Florian Rieder; Hans-Anton Lehr; Marc Dauer; Joachim Friedrich Kapp; Stefan Endres; Andreas Eigler
Journal:  J Pharmacol Exp Ther       Date:  2003-02-11       Impact factor: 4.030

8.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

9.  Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-kappaB.

Authors:  K Riehemann; B Behnke; K Schulze-Osthoff
Journal:  FEBS Lett       Date:  1999-01-08       Impact factor: 4.124

10.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice.

Authors:  L A Dieleman; B U Ridwan; G S Tennyson; K W Beagley; R P Bucy; C O Elson
Journal:  Gastroenterology       Date:  1994-12       Impact factor: 22.682

View more
  6 in total

1.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

2.  Effects of urtica dioica extract on experimental acute pancreatitis model in rats.

Authors:  Baris Yilmaz; Omer Basar; Bora Aktas; Akif Altinbas; Fuat Ekiz; Fatih Büyükcam; Aynur Albayrak; Zeynep Ginis; Gülfer Oztürk; Sahin Coban; Engin Ucar; Oskay Kaya; Osman Yüksel; Sedat Caner; Tuncay Delibasi
Journal:  Int J Clin Exp Med       Date:  2014-05-15

Review 3.  The globalization of traditional medicine in northern peru: from shamanism to molecules.

Authors:  Rainer W Bussmann
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-28       Impact factor: 2.629

Review 4.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

5.  A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Reishi Mushroom (Ganoderma lucidum), Stinging Nettle (Urtica dioica), and Epimedium (Epimedium sagittatum).

Authors:  Jarred Younger; Emily K Donovan; Kathleen S Hodgin; Timothy J Ness
Journal:  Int J Environ Res Public Health       Date:  2021-04-01       Impact factor: 3.390

Review 6.  Medicinal plants--prophylactic and therapeutic options for gastrointestinal and respiratory diseases in calves and piglets? A systematic review.

Authors:  Hannah Ayrle; Meike Mevissen; Martin Kaske; Heiko Nathues; Niels Gruetzner; Matthias Melzig; Michael Walkenhorst
Journal:  BMC Vet Res       Date:  2016-06-06       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.